A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Status:
RECRUITING
Trial end date:
2027-09-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
The main objectives of this study are :
* To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101
* to show preliminary antitumor activity in patients with advanced solid tumors
Participants will:
* Receive intravenous (IV) infusions of TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose.
* Undergo regular tumor imaging to assess response.
* Provide blood samples for pharmacokinetics (PK) and biomarker analysis.
* Be monitored for side effects and overall tolerability.
This study is being conducted in adult patients with advanced or metastatic solid tumors who have exhausted standard treatment options